Progyny Inc
$ 18.12
1.06%
17 Apr - close price
- Market Cap 1,484,068,000 USD
- Current Price $ 18.12
- High / Low $ 18.51 / 17.93
- Stock P/E 27.45
- Book Value 6.24
- EPS 0.66
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.12 %
- 52 Week High 28.75
- 52 Week Low 16.10
About
Progyny, Inc., a benefits management company, specializes in fertility benefits and family development solutions for employers in the United States. The company is headquartered in New York, New York.
Analyst Target Price
$27.45
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-25 | 2024-11-12 | 2024-08-06 | 2024-05-09 | 2024-02-27 | 2023-11-07 | 2023-08-03 | 2023-05-08 |
| Reported EPS | 0.48 | 0.45 | 0.19 | 0.48 | 0.42 | 0.4 | 0.17 | 0.17 | 0.13 | 0.16 | 0.15 | 0.18 |
| Estimated EPS | 0.14 | 0.13 | 0.16 | 0.4457 | 0.37 | 0.13 | 0.17 | 0.13 | 0.11 | 0.12 | 0.1 | 0.07 |
| Surprise | 0.34 | 0.32 | 0.03 | 0.0343 | 0.05 | 0.27 | 0 | 0.04 | 0.02 | 0.04 | 0.05 | 0.11 |
| Surprise Percentage | 242.8571% | 246.1538% | 18.75% | 7.6958% | 13.5135% | 207.6923% | 0% | 30.7692% | 18.1818% | 33.3333% | 50% | 157.1429% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.23 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PGNY
2026-04-18 05:40:32
Wall Street Zen has upgraded Progyny (NASDAQ:PGNY) from a "hold" to a "buy" rating. This upgrade follows Progyny beating Q4 earnings estimates with an EPS of $0.48 and revenue of $318.4 million, and providing strong FY2026 guidance. The stock currently trades around $18, with analysts maintaining a "Moderate Buy" consensus and an average price target of $27.91, suggesting significant upside potential.
2026-04-17 21:38:58
Progyny (PGNY) saw an 8.5% stock increase following the introduction of Progyny Select, a new fertility and family-building plan for small U.S. employers, and proposed governance changes to reduce supermajority voting thresholds. These initiatives aim to expand Progyny's market reach and enhance shareholder influence, though competitive and cost-cutting pressures from employers remain key risks. The company forecasts significant revenue and earnings growth by 2028, with current fair value estimates suggesting a substantial upside.
2026-04-17 09:10:22
Progyny has launched Progyny Select, the first fully insured supplemental fertility and family building plan designed for small U.S. employers. This new offering aims to provide predictable costs and expand access to comprehensive, outcomes-based family building and women's health care. The plan includes Progyny's managed provider network, Smart Cycle benefit, and personalized member navigation, making high-quality fertility and women's health benefits more accessible to a wider range of businesses.
2026-04-17 07:40:30
Progyny (Nasdaq: PGNY) has launched Progyny Select, the first fully insured, comprehensive supplemental fertility and family building plan designed for small U.S. employers. This new offering aims to provide predictable costs and expand access to high-quality women's health and family building benefits, addressing the growing need for fertility coverage in the workplace. The plan includes a managed provider network, Smart Cycle benefit, and personalized member navigation, making comprehensive care more accessible for smaller businesses looking to attract and retain talent.
2026-04-17 03:39:11
Progyny (PGNY) saw an 8.5% rise after launching Progyny Select, a new fertility and family-building plan for small U.S. employers, and announcing plans for stockholder approval to reduce supermajority voting thresholds. These strategic moves are expected to boost growth opportunities and increase shareholder influence over corporate decisions. The article suggests this combination could reshape Progyny’s growth prospects and investment narrative, though risks related to employer budgeting and competition remain.
2026-04-17 00:39:11
Progyny CEO Pete Anevski discussed infertility and IVF treatment benefits in the workplace with Jon Hansen. Anevski explained what Progyny does and why employers should include fertility and family-building benefits in their healthcare plans. This interview highlights the growing importance of comprehensive reproductive health coverage for employees.
